Compare Flowserve Corporation Common Stock (FLS) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flowserve Corporation Common Stock vs Natera Inc. Common Stock — how do they compare? Flowserve Corporation Common Stock trades at $69.92 (market cap $9.08B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 6.3× Flowserve Corporation Common Stock's market cap, and Flowserve Corporation Common Stock pays a 1.23% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Flowserve Corporation Common Stock for 6 Days and Natera Inc. Common Stock for 0 Days on average.
| FLS | NTRA | |
|---|---|---|
Market Cap | $9.08B | $57.03B |
Volume | 1,742,251 | 1,131,157 |
Sector | Industrials | Health |
52-Week High | $92.04 | $425.64 |
52-Week Low | $50.41 | $179.42 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $10.67B | $56.18B |
Dividend Yield | 1.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLS trades at $71.47, up 1.16% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q3 2026 results pending. Revenue for 2025 was $4.73 billion, with a net income margin of 8.01%. Recent news includes a new CFO appointment and a quarterly dividend declaration.
The outlook is mixed: strong fundamentals and a consensus price target of $90.75 suggest upside, but technical weakness and a high P/E of 24.9 pose risks. Key opportunities include strategic acquisitions and nuclear market exposure, while headwinds include weak organic sales and rising debt levels noted by analysts.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Flowserve Corporation Common Stock
Flowserve Corporation is a Texas-based manufacturer of engineered flow-control equipment, producing industrial pumps, mechanical seals, valves, and automation products through its Flowserve Pumps Division and Flow Control Division, serving the oil and gas, chemical, power, and water industries in more than 50 countries.
Read more on FLS →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
